Kazia Therapeutics (KZIA) Competitors $3.02 -0.01 (-0.33%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends KZIA vs. ACAB, ALRN, BIVI, CDIO, VIRI, DYAI, ESLA, ICCC, GANX, and PASGShould you be buying Kazia Therapeutics stock or one of its competitors? The main competitors of Kazia Therapeutics include Atlantic Coastal Acquisition Corp. II (ACAB), Aileron Therapeutics (ALRN), BioVie (BIVI), Cardio Diagnostics (CDIO), Virios Therapeutics (VIRI), Dyadic International (DYAI), Estrella Immunopharma (ESLA), ImmuCell (ICCC), Gain Therapeutics (GANX), and Passage Bio (PASG). These companies are all part of the "pharmaceutical products" industry. Kazia Therapeutics vs. Atlantic Coastal Acquisition Corp. II Aileron Therapeutics BioVie Cardio Diagnostics Virios Therapeutics Dyadic International Estrella Immunopharma ImmuCell Gain Therapeutics Passage Bio Atlantic Coastal Acquisition Corp. II (NASDAQ:ACAB) and Kazia Therapeutics (NASDAQ:KZIA) are both small-cap unclassified companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, community ranking, valuation, analyst recommendations, dividends, media sentiment, institutional ownership, risk and earnings. Do analysts prefer ACAB or KZIA? Kazia Therapeutics has a consensus target price of $20.00, suggesting a potential upside of 562.25%. Given Kazia Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Kazia Therapeutics is more favorable than Atlantic Coastal Acquisition Corp. II.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Atlantic Coastal Acquisition Corp. II 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Kazia Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk & volatility, ACAB or KZIA? Atlantic Coastal Acquisition Corp. II has a beta of 0.01, meaning that its stock price is 99% less volatile than the S&P 500. Comparatively, Kazia Therapeutics has a beta of 1.98, meaning that its stock price is 98% more volatile than the S&P 500. Does the media favor ACAB or KZIA? In the previous week, Atlantic Coastal Acquisition Corp. II's average media sentiment score of 0.00 equaled Kazia Therapeutics'average media sentiment score. Company Overall Sentiment Atlantic Coastal Acquisition Corp. II Neutral Kazia Therapeutics Neutral Does the MarketBeat Community believe in ACAB or KZIA? Kazia Therapeutics received 79 more outperform votes than Atlantic Coastal Acquisition Corp. II when rated by MarketBeat users. CompanyUnderperformOutperformAtlantic Coastal Acquisition Corp. IIN/AN/AKazia TherapeuticsOutperform Votes7952.67% Underperform Votes7147.33% Do insiders & institutionals have more ownership in ACAB or KZIA? 23.3% of Atlantic Coastal Acquisition Corp. II shares are owned by institutional investors. Comparatively, 30.9% of Kazia Therapeutics shares are owned by institutional investors. 91.2% of Atlantic Coastal Acquisition Corp. II shares are owned by insiders. Comparatively, 1.0% of Kazia Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has stronger valuation & earnings, ACAB or KZIA? Atlantic Coastal Acquisition Corp. II has higher earnings, but lower revenue than Kazia Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAtlantic Coastal Acquisition Corp. IIN/AN/AN/AN/AN/AKazia Therapeutics$2.31M5.70-$17.56MN/AN/A Is ACAB or KZIA more profitable? Company Net Margins Return on Equity Return on Assets Atlantic Coastal Acquisition Corp. IIN/A N/A N/A Kazia Therapeutics N/A N/A N/A SummaryKazia Therapeutics beats Atlantic Coastal Acquisition Corp. II on 7 of the 8 factors compared between the two stocks. Ad DTICackling Kamala hates this companyDo you want to see one of the most exciting election trades of all time? A trade that could help America become 100% energy independent… Reduce energy costs to virtually zero… And hand investors what could be a stunning return in just a few years’ time? It all has to do with a little known company that is helping to kick off the next great American energy revolution. Before that happens, you need to see the details here. Get Kazia Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KZIA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KZIA vs. The Competition Export to ExcelMetricKazia TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$13.20M$6.57B$5.12B$9.07BDividend YieldN/A2.98%4.91%4.22%P/E RatioN/A10.5991.3417.19Price / Sales5.70195.381,116.59116.80Price / CashN/A57.1642.6437.86Price / Book-1.535.104.794.78Net Income-$17.56M$151.51M$120.07M$225.60M7 Day Performance-14.93%-2.15%-1.89%-1.24%1 Month Performance-45.39%-3.14%11.45%3.36%1 Year Performance-21.56%11.50%30.61%16.58% Kazia Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KZIAKazia Therapeutics1.7324 of 5 stars$3.02-0.3%$20.00+562.3%-25.4%$13.20M$2.31M0.0012Gap UpACABAtlantic Coastal Acquisition Corp. IIN/A$5.77-47.1%N/A-45.7%$47.14MN/A0.004High Trading VolumeALRNAileron Therapeutics3.0723 of 5 stars$2.16-4.4%$19.00+779.6%-43.5%$46.81MN/A-0.729BIVIBioVie1.1623 of 5 stars$2.58-2.3%$3.00+16.3%+47.3%$45.84MN/A-0.2310CDIOCardio Diagnostics2.6566 of 5 stars$1.13-10.1%$2.00+76.6%-55.7%$45.81M$35,688.000.007Gap UpHigh Trading VolumeVIRIVirios TherapeuticsN/A$2.36-2.1%$3.00+27.1%+287.1%$45.45MN/A-8.745DYAIDyadic International1.643 of 5 stars$1.51-7.4%$6.00+297.4%+12.2%$44.68M$3.36M-7.097Gap DownESLAEstrella Immunopharma0.1513 of 5 stars$1.21+1.6%N/A-7.2%$43.87MN/A-4.50N/AGap DownICCCImmuCellN/A$4.90-0.4%N/A-7.9%$43.67M$23.84M-9.8475Positive NewsGap DownGANXGain Therapeutics2.4871 of 5 stars$1.630.0%$7.25+344.8%-36.1%$43.23M$50,000.00-1.4820PASGPassage Bio2.6866 of 5 stars$0.70-7.9%$7.75+1,008.6%-19.0%$43.18MN/A0.00130 Related Companies and Tools Related Companies ACAB Alternatives ALRN Alternatives BIVI Alternatives CDIO Alternatives VIRI Alternatives DYAI Alternatives ESLA Alternatives ICCC Alternatives GANX Alternatives PASG Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:KZIA) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTop Picks for Trump’s Pro-Crypto AmericaCoins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over...Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kazia Therapeutics Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Kazia Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free KZIA Stock Alerts